Study of SHR-A1811 with or without letrozole before surgery for early breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new drug called SHR-A1811, given either alone or with the hormone therapy letrozole, before surgery for women with early-stage breast cancer that is hormone receptor positive and HER2-low. The goal is to see if this treatment can shrink the tumor before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- You have been diagnosed with early-stage (stage II or III) invasive breast cancer that is hormone receptor positive and HER2-low.
- You have not received any prior cancer treatment for this breast cancer.
- You have at least one tumor that can be measured on imaging tests like CT or MRI.
- Your overall health is good, with an ECOG score of 0 or 1, meaning you are fully active or only slightly restricted.
- You are willing to use effective birth control during the study and for 6 months after treatment if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (SHR-A1811 with fulvestrant, with or without HS-10352) for women with advanced or metastatic breast cancer that has not been treated with systemic therapy before. It aims to see if these drugs can help slow or stop the cancer's growth.
This trial tests a new antibody-drug conjugate, SHR-A1811, against the combination of pyrotinib and capecitabine in people with HER2-positive advanced breast cancer that no longer responds to trastuzumab (Herceptin). Researchers want to see if SHR-A1811 works better than the standard treatment.
This study tests a new drug, SHR-A1811, for women with HER2-positive breast cancer that has spread to the brain. The trial will see if the drug can shrink tumors in the brain and body.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This trial tests a new drug, SHR-1811, combined with carboplatin for advanced breast cancer that has HER2 expression (including low levels). It is for people who have already tried standard treatments and their cancer has spread or cannot be removed by surgery.
This trial tests a new drug called SHR-A1811 combined with pertuzumab given before surgery to shrink tumors in people with early or locally advanced, hormone receptor-positive and HER2-positive breast cancer. It is designed to see if this combination can help reduce tumor size better.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.